'김갑성' 기자의 전체기사
-
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expa…
[ 메디채널 김갑성 기자 ] Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistance The study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological data in prior immune-oncology refractory or relapsed patients including anti-PD- (L)1 checkpoint inhibitor, with improved safety, compared to the prior Q2W schedule Th
- 김갑성 기자
- 2025-12-11 14:12
-
OTR Therapeutics and Zealand Pharma enter multi-program…
[ 메디채널 김갑성 기자 ] Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseases OTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30 million under certain pre-agreed conditions, and is eligible for potential preclinical, development, regulatory, and commercial milestone payments, for a potential total consideration of up to USD ~2
- 김갑성 기자
- 2025-12-11 14:00
-
Rhinocare Korea Accelerates Global Expansion with Singap…
[ 메디채널 김갑성 기자 ] K-Healthtech Firm Targets Rapid Global Scale-Up with Drug-Free Nasal-Care Innovation SINGAPORE and SEOUL, South Korea, Dec. 11, 2025 -- Rhinocare Korea, a medtech innovator specializing in drug-free respiratory care, announced plans to establish a joint venture (JV) in Singapore as part of its strategy to expand across Asia-Pacific, Europe, and North America. The move follows strong global interest in its patented JetStream™ warm-steam nasal therapy device—an at-home solution that alleviates nasal congestion using only water, without medication or invasive procedures.
- 김갑성 기자
- 2025-12-11 12:46
-
Updated Efficacy Data of Ivonescimab Combined with Chemo…
HONG KONG, Dec. 11, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) at the 2025 European Society for Medical Oncology Immuno-Oncology Congress (ESMO IO) in London, UK. Based on positive efficacy and safety profile, the ivonescimab combination therapy for first-line TNBC
- 김갑성 기자
- 2025-12-11 09:53
-
Hakka Medicine: From Millennia of Heritage to Modern Industr…
HONG KONG, Dec. 11, 2025 -- Hakka medicine is the result of deep integration between traditional Central Plains Chinese medicine and the natural environment of southern China, carrying profound historical heritage and unique clinical value. The Seventh World Hakka Entrepreneurs Convention was held in Meizhou, Guangdong from November 23 to 25. With the theme of "Gather Global Hakka Entrepreneurs • Facilitate High-Quality Development", the conference upheld the principles of "openness, innovation, cooperation, and mutual benefit," and explored new opportunities for the deve
- 김갑성 기자
- 2025-12-11 08:00
-
리스 파마슈티컬, 스타카토 원 브레스 테크놀로지 플랫폼 및 자산 인수... 파이프라인 확장 및…
광범위한 치료 잠재력을 가진 독자적 플랫폼 기술 '스타카토 원 브레스 테크놀로지' 인수 리스 팜의 기존 제품 파이프라인과 시너지 및 상호 보완 효과 UCB와의 글로벌 파트너십 하에 '스타카토 알프라졸람'의 라이선스 제공자 및 제조사 권리 획득 홍콩 2025년 12월 11일 -- 리스 파마슈티컬 홀딩스(Lee's Pharmaceutical Holdings Limited, 이하 "리스 팜")의 100% 자회사인 델라웨어 법인 노바 뉴마(Nova Pneuma Inc., 이하 "NPI")는 오늘 알렉자 파마슈티컬스(Alexza Pharmaceuticals, Inc., 이하 "알렉자")로부터의 자산 인수를 발표했다. 이번 거래로 리스 팜과 NPI는 지적재산권, 노하우, 상표, 제품 파이프라인, 장비, 제품 및 GMP(의약품 제조 및 품질 관리 기준) 시설 접근권을 포함한 '스타카토 원 브레스 테크놀로지(Staccato(R) One Breath Technology(R), 이하 "스타카토 OBT")' 플랫폼 및 자산에 대한 완전한 소유권을 확보하게 됐다.
- 김갑성 기자
- 2025-12-11 08:00
-
Samsung Biologics recognized as a global leader in wate…
Company receives the highest Water Security rating in two years into participation Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 11, 2025 -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from the Carbon Disclosure Project (CDP) an 'A' rating in Water Security. Two years into its participation in CDP assessments, Samsung Biologics has earned the top rating in Water Security, one rating higher than last year.
- 김갑성 기자
- 2025-12-11 07:30
-
Telix and Varian Announce Strategic Theranostics-EBRT Cli…
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic products and external beam radiation therapy (EBRT). EBRT is a widely used and validated treatment suitable for most solid malignant tumors. This treatment is typically delivered by radiation oncologists who play a central role
- 김갑성 기자
- 2025-12-11 03:30
-
DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS A…
New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. The new NIAHO® ASC Accreditation Program today received official approval from the US Centers for Medicare and Medicaid Services (CMS). Ambulatory surgery centers, also known as outpatient or day surgery clinics, are among the fastest-growing seg
- 김갑성 기자
- 2025-12-10 22:32
-
DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS
New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. Ambulatory surgery centers, also known as outpatient or day surgery clinics, are among the fastest-growing segments in global healthcare. They offer a wide range of outpatient procedures and help reduce the burden on hospital systems by managing rou
- 김갑성 기자
- 2025-12-10 22:16
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-31_SAT
- Sanyou Bio's Decade: From an Intelligent Super-Trillion Antibody Library to the "Innovation Hub for Original Drug Discovery" 16:15
- CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK 12:05
- Origin Agritech Announces Fiscal Year 2025 Results 06:00
- White Pearl Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering 05:47
- Planet Green Holdings Corp. Provides Response to Unusual Market Action 05:05
- SKF completes previously announced divestment of non-core aerospace operation in Elgin, USA 03:36
- DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion 03:34
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 31일 17시 40분